Target family: CD molecules (type: other_protein)
Target: CD20 (membrane-spanning 4-domains, subfamily A, member 1)

Ligand: veltuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.4399995803833 pKd
Reference (Journal): Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Published in: Clin Cancer Res

Ligand: ublituximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2022), EMA (2023)
Primary target: yes
Median affinity:  -
Reference (Journal): Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Published in: Leukemia

Ligand: tositumomab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity:  -

Ligand: rituximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (1997), EMA (1998)
Primary target: yes
Median affinity: 8.510000228881836 pKd
Reference (Journal): Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Published in: Clin Cancer Res

Ligand: ofatumumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2009), EMA (2010)
Primary target: yes
Median affinity: 9.920000076293945 pKd
Reference (Patent): Fully human antibodies against human cd20.

Ligand: odronextamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Published in: Sci Rep

Ligand: ocrelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2017), EMA (2018)
Primary target: yes
Median affinity: 9.079999923706055 pKd
Reference (Patent): Immunoglobulin variants and uses thereof

Ligand: obinutuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: yes
Median affinity:  -
Reference (Journal): Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Published in: Blood

Ligand: obinutuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: yes
Median affinity:  -
Reference (Journal): Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab.
Published in: Leuk Lymphoma

Ligand: mosunetuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Published in: Sci Transl Med

Ligand: ibritumomab tiuxetan (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2002), EMA (2004)
Primary target: yes
Median affinity:  -

Ligand: glofitamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA & EMA (2023)
Primary target: no
Median affinity: 8.319999694824219 pEC50
Reference (Journal): CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Published in: Clin Cancer Res

Ligand: epcoritamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA & EMA (2023)
Primary target: no
Median affinity:  -
Reference (Journal): DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Published in: EBioMedicine

Ligand: divozilimab (Antibody)
Interaction type: Antibody
Action: None
Ligand approved: yes
Approval source: Russia (2023)
Primary target: yes
Median affinity:  -

Ligand: BsAb (CD89-CD20) (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.029999732971191 pKd
Reference (Journal): CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.
Published in: Oncoimmunology